Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug, Pfizer is officially in the PD-1 x VEGF business, in-licensing a Chinese molecule of its own…
https://www.businesswire.com/news/home/20250519321225/en/Pfizer-Enters-into-Exclusive-Licensing-Agreement-with-3SBio
3SBio has registered a Ph3 clinical trial of its PD-1/VEGF bispecific antibody SSGJ-707 #SSGJ707 h2h pembrolizumab as 1L PD-L1-postive (PD-L1 TPS≥1%) NSCLC treatment
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.8¢ |
Change
-0.003(1.00%) |
Mkt cap ! $357.7M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.0¢ | $75.08K | 306.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 49366 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 219442 | 14 |
View Market Depth
| Last trade - 11.25am 18/06/2025 (20 minute delay) ? |
| IMM (ASX) Chart |